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Liquid biopsies focusing on the analysis of cell-free circulating tumor DNA
(ctDNA) may have important clinical implications for personalized medi-
cine, including early detection of cancer, therapeutic guidance, and moni-
toring of recurrence. Mutations in the oncogene, PIK3CA, are frequently
observed in breast cancer and have been suggested as a predictive biomar-
ker for PI3K-selective inhibitor treatment. In this study, we analyzed the
presence of PIK3CA mutations in formalin-fixed, paraffin-embedded, meta-
static tissue and corresponding ctDNA from serum of patients with
advanced breast cancer using a highly sensitive, optimized droplet digital
PCR (ddPCR) assay. We found 83% of patients with PIK3CA mutation in
the metastatic tumor tissue also had detectable PIK3CA mutations in
serum ctDNA. Patients lacking the PIK3CA mutation in corresponding
serum ctDNA all had nonvisceral metastatic disease. Four patients with
detectable PIK3CA-mutated ctDNA were followed with an additional
serum sample during oncological treatment. In all cases, changes in
PIK3CA ctDNA level correlated with treatment response. Our results
showed high concordance between detection of PIK3CA mutations in
tumor tissue and in corresponding serum ctDNA and suggest that serum
samples from patients with advanced breast cancer and ddPCR may be
used for PIK3CA mutation status assessment to complement imaging tech-
niques as an early marker of treatment response.
Abbreviations
bp, base pairs; CT, computed tomography; ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction; FFPE, formalin-
fixed and paraffin-embedded; HE, hematoxylin–eosin; HER2, human epidermal growth factor receptor 2; PET, positron emission
tomography; PTEN, phosphatase and tensin homolog; SOP, standard operating procedure.
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1. Introduction
Cell-free DNA is released from both normal and can-
cer cells into the circulation (Choi et al., 2005; Stroun
et al., 2000). In contrast to benign tumors and other
noncancerous conditions, a rapid turnover of tumor
cells is thought to result in a consistently increased
release of circulating tumor DNA (ctDNA; Diehl
et al., 2005). This enables clinical use of repeated and
noninvasive blood samples as a ‘liquid biopsy’ to mon-
itor the dynamic evolution of human cancers (Sira-
vegna et al., 2017) and response to treatment, which
could accompany the well-established RECIST 1.1 and
PERCIST 1.0 criteria evaluative of changes in tumor
burden during cancer treatment (Eisenhauer et al.,
2009).
In some cancers, certain driver mutations are found
at high frequencies, such as KRAS in colorectal cancer
(Hao et al., 2017). In other cancers, including breast
cancer, the pattern of driver mutations is more diverse.
The most frequent driver mutation observed in breast
cancer other than TP53 is PIK3CA, an oncogene encod-
ing the p110a component of the phosphoinositide 3-
kinase (PI3K). Genetic alterations in PI3K pathway
constituents, for example, PI3K-activating mutations,
loss of the antagonistic tumor suppressor phosphatase,
and tensin homolog or via the transduction of aberrant
receptor tyrosine kinase signals, result in upregulation
of the PI3K pathway (Saal et al., 2005; Stemke-Hale
et al., 2008). Abnormal activation of the PI3K pathway
is a common finding in a variety of tumor types, includ-
ing breast cancer, and the recent BELLE-2 study of the
PI3K inhibitor, Buparlisib, showed promising results in
progression-free survival in combination with endocrine
therapy, especially in patients with tumors exhibiting
PIK3CA mutations (Baselga et al., 2017). Additional
PI3K inhibitors are currently under clinical develop-
ment (Zhao et al., 2017).
PIK3CA mutations are present in approximately 30–
40% of all breast cancers (Arsenic et al., 2014; Buttitta
et al., 2006; Campbell et al., 2004; Jensen et al., 2011;
Koboldt et al., 2012; Li et al., 2006; Maruyama et al.,
2007; Saal et al., 2005), with the highest frequency in
estrogen receptor (ER)-positive and human epidermal
growth factor receptor (HER)2-positive breast cancers
(Koboldt et al., 2012; Saal et al., 2005). The four most
frequent ‘hotspot’ PIK3CA mutations are located
within two exons (exon 9: E545K and E542K and
exon 20: H1047R and H1047L) and account for 80–
90% of all PIK3CA mutations in human malignancies
(Kalinsky et al., 2009; Karakas et al., 2006). We
(Kodahl et al., 2015) and others (Oshiro et al., 2015)
have previously reported disputed points concerning
the use of ctDNA containing PIK3CA mutations as a
biomarker in early-stage breast cancer patients. The
ctDNA amount is influenced by the extent of the dis-
ease, including tumor burden, and generally, very little
tumor DNA is present in the circulation in early-stage
breast cancers compared to advanced stage (Diehl
et al., 2005). Increasing the blood sample volume to be
analyzed as well as technological improvements that
increase sensitivity to detection of ctDNA in low blood
concentrations is necessary to achieve better assay
results (Han et al., 2017). However, ctDNA containing
PIK3CA mutations has been suggested to be a promis-
ing biomarker of cancer patients with advanced disease
both for early detection of recurrence and to monitor
treatment response (Board et al., 2010; Dawson et al.,
2013; Higgins et al., 2012), and studies reveal a corre-
lation of PIK3CA mutation level and tumor burden in
advanced breast cancer (Garcia-Saenz et al., 2017;
Higgins et al., 2012).
This study aimed to investigate whether PIK3CA
mutations identified in archived formalin-fixed, paraf-
fin-embedded (FFPE), metastatic tissue samples of
breast cancer patients could also be detected in their
corresponding ctDNA from serum samples using an
optimized droplet digital PCR (ddPCR) assay (Kodahl
et al., 2015). Furthermore, we sought to investigate
whether the level of PIK3CA-mutated ctDNA could
be used as an early marker for monitoring treatment
response and supporting clinicians in guiding treat-
ment decisions.
2. Materials and methods
2.1. Patient samples
Metastatic tumor biopsies and corresponding serum
samples were obtained from 66 patients who were part
of a prospective study, in which patients from 2007 to
2013 were offered a biopsy from the metastasis, when
diagnosed with recurrent breast cancer at the Depart-
ment of Oncology at Odense University Hospital. Six-
teen of the included 66 patients had previously had
their metastatic tumor tissue analyzed for PIK3CA
mutations using pyrosequencing (Jensen et al., 2011).
In this study, the tumor biopsies and corresponding
serum samples from these 16 patients, in addition to
the other 50 patients, were analyzed for PIK3CA
mutations using ddPCR (Section 2.2).
Blood was drawn into BD VacutainerTM, SSTTM
Serum Separation Tubes with polymer gel/silica activa-
tor. According to standard operating procedure, serum
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was prepared within one hour of sample collection
after centrifugation (2000G, 1800 g; 10 min at 20 °C)
and immediately stored at 80 °C.
Hematoxylin–eosin (HE) sections were prepared from
FFPE, tissue biopsies from metastatic sites and reviewed
by a skilled breast pathologist to confirm the presence
and amount of tumor tissue. Cancer cell content in all
cases was > 30%. For DNA extraction, 2 9 10 lm sec-
tions of FFPE samples from each tumor sample were
used. Follow-up data, including patient outcome, were
available for all patients, and observations on follow-up
were censored at date of data withdrawal (March 2018).
Overall survival is defined as time to death. An overall
survival curve was generated by Kaplan–Meier survival
analysis using STATA statistical software (StataCorp
LLC, College Station, TX, USA). The experiments were
undertaken with the understanding and written consent
of each patient. The study methodologies conformed to
the standards set by the Declaration of Helsinki. The
study was approved by The Regional Scientific Ethical
Committee for Southern Denmark (ID: S-20070003)
and the Danish Data Protection Agency.
2.2. Droplet digital PCR of FFPE samples
Genomic DNA was extracted using a Maxwell 16
FFPE Tissue LEV DNA Purification Kit (Promega,
Madison, WI, USA) according to the manufacturer’s
recommendations. Purified DNA was eluted in 100 lL
and analyzed by ddPCR in a QX100 droplet digital sys-
tem (Bio-Rad, Copenhagen, Denmark) using Pri-
mePCRTM ddPCRTM Mutation Assays (Bio-Rad) for
wild-type PIK3CA as well as the four most common
mutations in the PIK3CA gene: E542K (c.1624G>A)
Assay ID PIK3CA:dHsaCP2000073 (mut) and
dHsaCP2000074 (wt), chromosome location
3:178936050–178936172, amplicon length 80 bp,
E545K (c.1633G>A) Assay ID PIK3CA:dHsaC-
P2000075 (mut) and dHsaCP2000076 (wt), chromo-
some location 3:178936068–178936190, amplicon
length 80 bp, H1047L (c.3140A>T) Assay ID PIK3CA:
dHsaCP2000123 (mut) and dHsaCP2000124 (wt), chro-
mosome location 3:178952024-178952146, amplicon
length 74 bp and H1047R (c.3140A>G) Assay ID
PIK3CA:dHsaCP2000077 (mut) and dHsaCP2000078
(wt), chromosome location 3:178952065-178952187,
amplicon length 80 bp. They were all performed in
duplicates, as described by the manufacturer. Five
microlitre sample DNA was combined with 1 lL 209
wild-type primers/probe mix (HEX-labeled) and 1 lL
209 target primers/probe mix (FAM-labeled) along
with 10 lL 29 ddPCR supermix for probes (Bio-Rad)
and 3 lL DNase-/RNase-free sterile water in a 20 lL
reaction volume. Droplets were generated from the
20 lL reaction mix and 70 lL droplet generator oil for
probes (Bio-Rad) in a droplet generator DG8 cartridge
(Bio-Rad), and the droplets were transferred into a
microtiter plate and subjected to thermal cycling, as
recommended by the manufacturer. Thermal cycle
parameters were as follows: enzyme activation 95 °C
for 10 min, followed by 40 cycles of denaturation
94 °C for 30 s and annealing/extension 55 °C for 60 s
with a ramp rate of 2 °C/s, and a final enzyme inactiva-
tion step 98 °C for 10 min. After PCR thermocycling,
the emulsions were enumerated by fluorescence mea-
surement using a QX100 (Bio-Rad) droplet reader.
Mutant populations were identified, and the fractional
abundance calculation of mutant to total PIK3CA
molecules was calculated for each sample using Poisson
statistics from the qx100 software (Bio-Rad).
2.3. Droplet digital PCR of serum samples
DNA was purified from 1 mL of serum using a MagNA
Pure LC Total Nucleic Acid Isolation Kit – large vol-
ume (Roche) according to the manufacturer’s instruc-
tions. Water was added to serum samples with
inadequate volumes to 1 mL prior to purification. Also
prior to purification, 5 lL non-human exogenous inter-
nal control DNA spike-in fragment of 191 bp was
added to each serum sample. The control fragment was
part of the soya bean CPP1 gene and generated by PCR
(Pallisgaard et al., 2015). Purified DNA was eluted in
100 lL in the supplied elution buffer. Twenty-five
microlitre of the purified DNA was used to control for
loss during purification by measuring the amount of the
added spike-in fragment by qPCR, contamination of
lymphocyte DNA by qPCR analysis of the
immunoglobulin gene rearrangements of B cells and
number of genomic DNA alleles per ml of serum, as
previously described (Pallisgaard et al., 2015). To
increase the sensitivity of the analysis, the remaining
75 lL serum DNA was subjected to 12 cycles of PCR
pre-amplification with Q5 High-Fidelity DNA Poly-
merase (New England BioLabs, Ipswich, MA, USA)
using a multiplex PIK3CA primer mix. The PIK3CA
ddPCR assay has been extensively validated as reported
in Kodahl et al. (2015). In short, serum DNA was up-
concentrated by centrifugation 10 min 12 000 g using a
Amicon Ultra-0.5 Centrifugal Filter Unit (Merck Milli-
pore, Burlington, MA, USA) and volume was adjusted
to 20 lL with DNase-/RNase-free sterile water. A mul-
tiplex pre-amplification step was incorporated prior to
ddPCR using the PIK3CA E542K and H1047L Pri-
mePCRTM ddPCRTM Mutation Assays (Bio-Rad) pri-
mers, diluted 1 : 9. Pre-amplification was performed in
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50 lL reactions using 20 lL of up-concentrated serum
DNA, 5 lL multiplex primer mix (100 nM final concen-
tration of each primer), and 25 lL Q5 Hot Start High-
Fidelity 2X Master Mix (New England BioLabs).
Thermal cycling was performed by enzyme activation
98 °C for 10 min, followed by 12 cycles of denatura-
tion 98 °C for 15 s, annealing 55 °C for 60 s and
extension 72 °C for 60 s, and a final enzyme inactiva-
tion step 99.9 °C for 10 min. The Q5 High-Fidelity
DNA Polymerase (New England BioLabs) and
TaqMan PreAmp Master Mix (Life Technologies,
Carlsbad, CA, USA) were tested for potential incorpo-
ration of technical mutations due to misincorporation
of the Taq polymerase during the pre-amplification step
by comparing the mutant allele fraction in samples from
healthy donors before and after pre-amplification
(Fig. 1). It should be noted that as the linearity of the
pre-amplification step was not experimentally verified
there may be a slight risk of a quantification bias due to
nonperfect linear pre-amplification. However, as the
wild-type and mutant amplicon only differs by one
nucleotide in the middle of the amplicon, it is very unli-
kely that the mutant/wild-type ratio will be affected dur-
ing the pre-amplification step. The pre-amplified
products were then diluted 50-fold, and ddPCR was per-
formed in duplicates for PIK3CA E542K, E545K,
H1047L, and H1047R mutation detection, according to
the manufacturer’s protocol (Bio-Rad). The results were
reported as a fractional abundance of mutant DNA alle-
les to total (mutant plus wild-type) DNA alleles. Posi-
tive control DNA fragments for the four PIK3CA
mutations were constructed and spiked into DNA from
healthy donors and used as positive controls, as previ-
ously described (Spindler et al., 2012).
From the nonmutated alleles, the level of blank (LoB)
for each of the four PIK3CA mutation assays was deter-
mined using pre-amplified cell-free plasma DNA and the
Q5 High-Fidelity DNA Polymerase (New England Bio-
Labs). The LoB % for each sample was calculated by the
formula: ((mut allele)/((mut allele) + (wt allele))) 9 100.
The standard deviation of the average LoB % was calcu-
lated, and the level of detection (LoD, with 95% confi-
dence) was determined by (LoB + (2 9 Std.dev of LoB)
(Table S1). LoD of the ddPCR assay allowed detection
of a mutant allele fraction of ≥ 0.08% (Table S1) corre-
sponding to one mutant molecule in a background of
1200 wild-type molecules.
2.4. Controls
Four 180-bp DNA fragments containing one of the
four PIK3CA mutations analyzed in this study were
generated by site-directed PCR mutagenesis, as previ-
ously described (Spindler et al., 2012). The mutated
PCR fragments were spiked into normal donor DNA
and used as positive controls throughout the study. In
all ddPCR and qPCR, positive and negative (water)
and wild-type (normal donor DNA) controls were per-
formed in parallel.
3. Results
3.1. Patient characteristics
Archived formalin-fixed, paraffin-embedded metastatic
tumor biopsies and corresponding serum samples were
available from 66 patients with metastatic disease who
were part of a prospective study (2007–2013) at the
Department of Oncology, Odense University Hospital,
Denmark (Fig. 2). Metastatic tissue samples from 16
patients had, as part of a previous study (Jensen et al.,
2011), been tested for the presence of PIK3CA muta-
tions by pyrosequencing, 15 of which were found to be
PIK3CA-mutation positive and one wild-type. In this
Fig. 1. Assay specificity for PIK3CA mutations. Comparison of mutant PIK3CA detection in human control genomic DNA (gDNA) and cell-
free plasma DNA following pre-amplification or no pre-amplification using Q5 High-Fidelity DNA Polymerase (New England BioLabs) or
TaqMan PreAmp Master Mix (Life Technologies). The level of blank (LoB) was 0.04% for the mutation E545K and for H1047R, 0.02% for
E542K, and less than 0.01% for H1047L as shown by the graphs.
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study, 50 additional patients were included to a total
of 66 patients. Of these 66 patients, four samples were
excluded due to less than 10% detectable tumor cells
in the FFPE tumor tissue, and two patients were
excluded due to missing serum samples, resulting in a
total of 60 matched samples. Serum samples from 24
patients with a PIK3CA mutation in their metastatic
tissue and five patients with PIK3CA wild-type meta-
static tissue (randomly selected) were analyzed for cir-
culating cell-free PIK3CA mutations using ddPCR
(Fig. 2). The survival curve from Kaplan–Meier esti-
mates of the 29 metastatic breast cancer patients
included for further analysis showed a median overall
survival of 20 months (Fig. S1).
3.2. PIK3CA mutation analysis of metastatic
breast cancer samples
PIK3CA mutations were observed in 40% of the total
metastatic tissue samples (24/60), with 33% (8/24) hav-
ing exon 9 mutations (E542K and E545K) and 67%
(16/24) having exon 20 mutations (H1047L and
H1047R), as determined by the optimized ddPCR
method. However, the inclusion of the preselected
samples might account for the high overall observed
frequency of PIK3CA mutations in tumor tissue com-
pared to the unselected samples (24%; 11/46).
Of the 24 breast cancer patients with PIK3CA muta-
tion-positive metastasis, 92% were ER-positive
(n = 22), 8% were ER-negative (n = 2), and 8% were
HER2-amplified (n = 2) (Table 1). The first blood sam-
ple from each patient was taken an average of 1.5 days
after diagnostic biopsy (range: 26 days before to
43 days after diagnosis) (Table 2). Of the 24 patients
with detectable PIK3CA mutations in the metastatic
tumor tissue, 20 (83%) had similar mutations detectable
in corresponding ctDNA from serum. Four patients
with PIK3CA mutations in metastatic tumor tissue had
no detectable mutations in their corresponding serum
samples, and interestingly, all had nonvisceral meta-
static disease. No patients with PIK3CA wild-type
tumor biopsies (n = 5) exhibited PIK3CA mutations in
their corresponding serum samples.
3.3. PIK3CA-mutated ctDNA as an early marker
for treatment response
Six patients had serial serum samples collected during
oncological treatment (four patients with detectable
ctDNA containing PIK3CA mutations and two wild-
type that remained wild-type) (Table 2). Response
evaluation was performed using computed tomography
(CT) or positron emission tomography (PET) imaging
according to RECIST 1.1 and PERCIST 1.0 (Eisen-
hauer et al., 2009) an average of 11.5 weeks after diag-
nostic biopsy (range: 9.5–15 weeks) (Table 2).
Clinicopathological patient characteristics is provided
in Table 1 and the results of the response evaluations
Fig. 2. Consort diagram. A total of 66 metastatic tumor biopsies and corresponding serum samples were prospectively collected. Of these,
24 metastasis with PIK3CA mutation and five wild-type as determined by ddPCR were selected for further analysis.
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is provided in Table 2. Correlation between ctDNA
PIK3CA mutation level, treatment, and disease history
for the four patients is shown in Fig. 3. Serum samples
from all four patients (patient nos 24, 25, 26, and 27)
showed a decreased level of PIK3CA-mutated ctDNA
in the second and, for one, third serum sample, sug-
gesting tumor shrinkage during treatment. This was
verified by CT or PET imaging showing partial
response in all four patients during treatment within
this follow-up period (Table 2 and Fig. 3). Unfortu-
nately, no additional serum samples were collected
from these patients.
4. Discussion
Tissue biopsy is an invasive procedure that may cause
distress as well as complications for the patient. More-
over, due to intratumoral heterogeneity, the use of
tumor tissue to obtain an accurate genomic landscape of
breast cancer could be challenging (Gerlinger et al.,
2012). Accurate determination of the genomic landscape
of breast tumors is important to identify driver muta-
tions that may make them susceptible to targeted antitu-
mor agents, but also to determine whether subclones
within the metastasis subsequently acquire additional
mutations that render the lesion drug-resistant, leading
to disease progression (Diaz et al., 2012). Metastatic
lesions are, unlike primary tumors, generally not surgi-
cally accessible and must be treated with systemic thera-
pies. To make decisions regarding targeted cancer
treatment, liquid biopsies, including detection of mutant
tumor DNA in the circulation, may be the future
method of choice to determine optimal treatment strat-
egy, monitor treatment response, and characterize
escaping resistant subclones that may cause metastases.
In this study, we show that PIK3CA mutations can
be identified in ctDNA of serum samples from patients
with PIK3CA-mutated metastatic breast cancer and
Table 1. Clinical characteristics of breast cancer patients with metastatic tissue and corresponding ctDNA from serum analyzed for PIK3CA
mutation.
Patient no. ER status HER2 status Site of metastatic disease Site of biopsy
1 + + Non-visceral Lymph nodes
2 +  Non-visceral Bone
3 +  Non-visceral Bone
4 +  Non-visceral Lymph nodes
5   Non-visceral Subcutis, chest wall
6 +  Visceral, Non-visceral Liver
7 +  Non-visceral Bone
8 +  Visceral Pleural effusion
9   Visceral, Non-visceral Lymph nodes
10 +  Non-visceral Bone
11 + NA Visceral, Non-visceral Lymph nodes
12 +  Visceral, Non-visceral Bone
13 +  Visceral, Non-visceral Liver
14 +  Non-visceral Bone
15 +  Non-visceral Bone
16 +  Visceral, Non-visceral Liver
17 +  Visceral, Non-visceral Liver
18 +  Non-visceral Subcutis, chest wall
19 +  Visceral, Non-visceral Liver
20 +  Non-visceral Lymph nodes
21 +  Visceral, Non-visceral Bone
22 +  Visceral, Non-visceral Liver
23 +  Visceral, Non-visceral Liver
24 + + Non-visceral Skin
25 +  Non-visceral Bone
26   Visceral, Non-visceral Liver
27 +  Visceral, Non-visceral Bone
28   Visceral, Non-visceral Subcutis
29 +  Visceral, Non-visceral Lymph nodes
ER+ cutoff was ≥1% positive tumor cells. Visceral metastases are metastases in the lung, liver, brain and/or peritoneum. Non-visceral local-
izations are the skin, lymph nodes, soft tissue and/or bone. NA, not available.
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that the circulating PIK3CA mutation level might be
used to follow treatment response in these patients.
Using an optimized, highly sensitive, ddPCR assay, we
found that 83% of patients with PIK3CA mutation in
the metastatic tumor tissue had detectable circulating
PIK3CA mutations in their corresponding serum sam-
ple, which underlines that the method is highly useful
to obtain information regarding tumor characteristics
and might be favored over the invasive and time con-
suming solid biopsies. Moreover, our study implies
that ctDNA is a resource for therapeutic guidance in
patients who may benefit from PI3K-selective inhibitor
treatment (Baselga et al., 2017).
Response evaluation during treatment of metastatic
breast cancer is currently assessed primarily by visual-
ization of imaging data and/or clinical examination of
the patient at monthly intervals. Liquid biopsies of
ctDNA may provide an additional method to monitor
tumor response to treatment. Although only four
patients with PIK3CA mutation in metastatic tumor
tissue were followed with serial serum samples, all
showed changes in PIK3CA ctDNA levels that corre-
lated with treatment response according to imaging
assessments. Similar results have been reported by
others (Garcia-Saenz et al., 2017), although no
correlation between PIK3CA mutation levels and treat-
ment response was observed in two of eight advanced
breast cancer patients (Garcia-Saenz et al., 2017).
Cases with discordance between PIK3CA mutation
level and treatment response could be explained by the
technology used (Kodahl et al., 2015) or the disease
stage (early-stage versus advanced breast cancer; Gar-
cia-Saenz et al., 2017; Kodahl et al., 2015), or may
reflect tumor evolution and heterogeneity within
advanced breast cancer disease. However, liquid biop-
sies have previously been suggested to reflect the glo-
bal (primary and metastatic sites) molecular status of
cancer in terms of tumor heterogeneity better than a
solid tumor biopsy (Crowley et al., 2013). While the
four patients followed with serial serum samples all
had H1047R mutations, we would expect similar
results for patients with other hotspot PIK3CA muta-
tions. Our results from analysis of the serial serum
samples suggest that the level of circulating PIK3CA
mutations could be a marker of disease burden in
patients with PIK3CA mutant tumors. However, hav-
ing a PIK3CA mutation does not necessarily mean
that the only effective treatment is PI3K-targeted and,
in the case of the patients we studied, tumor reduction
was caused by chemo or antihormonal therapies.
Fig. 3. Serial monitoring of PIK3CA point mutation levels and correlation with treatment response in patients with advanced breast cancer.
Measurements of serial fractional abundance of PIK3CA-mutated ctDNA (H1047R) and evaluation of treatment response by CT or PET
imaging in four patients (patient nos 24, 25, 26, and 27). Blood samples were collected two to three times per patient and the level of
PIK3CA-mutated ctDNA in serum reported as copieslL1 (■). Details regarding type of treatment (docetaxel, aromatase inhibitor (AI),
epirubicin, cyclophosphamide, or paclitaxel) and treatment schedule are indicated by colored shading. Time for biopsy and CT or PET
imaging is indicated by arrows. All patients showed partial response (PR) after treatment.
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Similar to our study, good concordance between
PIK3CA mutation status in formalin-fixed, paraffin-
embedded, biopsies and ctDNA of patients with meta-
static breast cancer has been observed by others (Gar-
cia-Saenz et al., 2017; Higgins et al., 2012).
Interestingly, the patients with PIK3CA mutation iden-
tified in the metastatic tissue but in whom similar muta-
tions could not be detected in corresponding serum
ctDNA all had nonvisceral metastatic disease, suggest-
ing that the location of the metastasis, in addition to
size, may influence the amount of tumor DNA shed into
the circulation. On the other hand, the sensitivity of the
ddPCR assay allowed detection of a mutant allele frac-
tion of > 0.084%, corresponding to one mutant mole-
cule in a background of 1200 wild-type molecules,
making it highly sensitive. A higher concordance
between PIK3CA mutation status in formalin-fixed,
paraffin-embedded, biopsies and ctDNA might have
been achieved if we had used plasma instead of serum,
as serum DNA can be contaminated by blood cell DNA
(Jen et al., 2000). However, the risk of contamination
was limited as serum was isolated within one hour from
blood drawing and subsequently immediately stored at
80 °C. Further, all DNA samples were tested for
potential blood cell DNA contamination by a novel
qPCR assay utilizing the immunoglobulin gene rear-
rangements in B cells (Pallisgaard et al., 2015).
5. Conclusions
In conclusion, our results show high concordance
between tumor tissue and ctDNA mutation status and
suggest that serum samples from advanced breast can-
cer patients and ddPCR may be used for PIK3CA
mutation status assessment to complement imaging
techniques as a tool for monitoring treatment
response. However, as not all metastatic breast cancers
are PIK3CA-positive, additional biomarkers in the
metastatic setting are needed.
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